Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats

European Journal of Pharmacology

Volumn 724, Issue 1, 2014, Pages 204-210

  Ibrahim, Mohamed A ^a   Amin, Entesar F ^a   Ibrahim, Salwa A ^a   Abdelzaher, Walaa Y ^a   Abdelrahman, Aly M ^a  

^a Minia University   (Egypt)

Author keywords

Fructose induced metabolic syndrome; Irbesartan; Montelukast

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CATALASE; FRUCTOSE; GLUTATHIONE; IRBESARTAN; LIPID; MALONALDEHYDE; MONTELUKAST; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER PROTECTION; MALE; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

FRUCTOSE-INDUCED METABOLIC SYNDROME; IRBESARTAN; MONTELUKAST;

ACETATES; ALANINE TRANSAMINASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; CASPASE 3; FRUCTOSE; INSULIN; LEUKOTRIENE ANTAGONISTS; LIPIDS; LIVER; LIVER DISEASES; MALE; METABOLIC SYNDROME X; QUINOLINES; RATS; RATS, WISTAR; TETRAZOLES;

EID: 84892638166     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.024     Document Type: Article

References (29)

1. M. Anjaneyulu, and K. Chopra Effect of irbesartan on the antioxidantdefense system and nitric oxide release in diabetic rat kidney Am. J. Nephrol. 24 2004 488 496
2. A. Astrup, and N. Finer Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes. Rev. 1 2000 57 59
3. M.S. Benninger, and H. Waters Montelukast: pharmacology, safety, tolerability and efficacy Clinical Med.: Ther. 1 2009 1253 1261 (begin-of-the-skype-highlighting)
4. J.A. Buege, and S.D. Aust Microsomal lipid peroxidation Methods Enzymol. 52 1978 302 310
5. V. Capra Molecular and functional aspects of human cysteinyl leukotriene receptors Pharmacol. Res. 50 2004 1 11
6. A.K. Coskun, M. Yigiter, A. Oral, F. Odabasoglu, Z. Halici, O. Mentes, E. Cadirci, F. Atalay, and H. Suleyman The effects of montelukast on antioxidant enzymes and proinflammatory cytokines on the heart, liver, lungs, and kidneys in a rat model of cecal ligation and puncture-induced sepsis Sci. World J. 11 2011 1341 1356 10.1100/tsw.2011.122
7. P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg Metabolic Syndrome:acomprehensive perspective based on interactions between obesity, diabetes, and inflammation Circulation 111 2005 1448 1454
8. G.O. Dengiz, F. Odabasoglu, Z. Halici, E. Cadirci, and H. Suleyman Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats J. Pharmacol. Sci. 105 2007 94 102
9. W.X. Ding, and X.M. Yin Dissection of the multiple mechanisms of TNF-induced apoptosis in liver injury J. Cell. Mol. Med. 8 2004 445 454
10. P. Faure, E. Rossini, N. Wiernspeger, M.J. Richard, A. Favier, and S. Halimi An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats Diabetes 48 1999 353 357
11. P.A. Hansen, D.H. Han, L.A. Nolte, M. Chen, and J.O. Holloszy DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet Am. J. Physiol. 273 1997 1704 1708
12. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, B. Dahlöf, U. de Faire, C. Mörlin, B.E. Karlberg, P.O. Wester, and J.E. Björck Effect of angiotensin-converting-enzyme inhibitioncompared with conventional therapy on cardiovascularmorbidity and mortality in hypertension: the Captopril PreventionProj199ect (CAPPP) randomised trial Lancet 353 1999 611 616
13. M. Ibrahim, E. Farghaly, W. Gomaa, M. Kelleni, and A. Abdelrahman Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease Eur. J. Pharmacol. 659 2011 289 295
14. B. Khan, S. Navalkar, Q. Khan, S. Rahman, and S. Parthasarathy Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease Clin. Study 38 2001 1662 1667
15. E. Kose, H.I. Sapmaz, E. Sarihan, N. Vardi, Y. Turkoz, and N. Ekinci Beneficial effects of montelukast against methotrexate-induced liver toxicity: a biochemical and histological study Sci. World J. 2012 10.1100/2012/987508 (EPub)
16. M. Martínez-Clemente, and Titos.E. Clària The 5-lipoxygenase/leukotriene pathway in obesity, insulinresistance, and fattyliverdisease Curr. Opin. Clin. Nutr. Metab. Care 14 2011 347 353
17. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and betacellfunction from fasting plasma glucose and insulin concentrations inman Diabetologia 28 1985 412 419
18. T. Nakagawa, H. Hu, S. Zharikov, K.R. Tuttle, R.A. Short, O. Glushakova, X. Ouyang, D.I. Feig, E.R. Block, J. Herrera-Acosta, l J.M. Pate, and R.J. Johnson A causalrole for uric acid in fructose-inducedmetabolicsyndrome Am. J. Physiol., Renal Physiol. 290 2006 F625 F631
19. T. Ogihara, K. Nakao, T. Fukui, K. Fukiyama, K. Ueshima, K. Oba, T. Sato, and T. Saruta Candesartan antihypertensive survival evaluation in Japan trial group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 51 2008 393 398
20. A. Otunctemur, E. Ozbek, M. Cekmen, S.S. Cakir, M. Dursun, E.C. Polat, A. Somay, and N. Ozbay Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney Ren Fail 35 2013 403 410
21. E. Ozkan, C. Akyüz, A.O. Sehirli, U. Topaloǧlu, F. Ercan, and G. Sener Montelukast, a selective cysteinyl leukotriene receptor 1 antagonist, reduces cerulein-induced pancreatic injury in rats Pancreas 39 2010 1041 1046
22. S.K. Panchal, H. Poudyal, and L. Brown Quercetin ameliorates cardiovascular, hepatic and metabolic changes in diet-induced metabolic syndrome in rats J. Nutr. 142 2012 1026 1032
23. K.G. Parhofer, F. Münzel, and M. Krekler Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study Cardiovasc. Diabetol. 6 2007 36 10.1186/1475-2840-6-36
24. R.S. Rector, J.P. Thyfault, Y. Wei, and J.A. Ibdah Non-alcoholic fatty liver disease and the metabolic syndrome: an update World J. Gastroenterol. 14 2008 185 192
25. G. Riccioni, T. Bucciarelli, B. Mancini, C. DiIlio, and N. D'Orazio Antileukotriene drugs: clinical application, effectiveness and safety Curr. Med. Chem. 14 2007 1966 1977
26. S.E. Shoelson, J. Lee, and A.B. Goldfine Inflammation and insulin resistance J. Clin. Invest. 116 2006 1793 1801
27. D. Stellato, L.F. Morrone, C. Di Giorgio, and L. Gesualdo Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? Intern. Emerg. Med. 7 2012 5 8
28. S. Takai, D. Jin, and M. Miyazaki Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ J. Pharmacol. Sci. 116 2011 309 315
29. H. Tugtepe, G. Sener, S. Cetinel, A. Veliogu-Ogunc, and B.C. Yegen Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist Eur. J. Pharmacol. 557 2007 69 75